Biogen (BIIB.US) and UCB's new lupus drug, Dupixent, succeeds in late-stage trials, reversing early failure shadow

Biogen (BIIB.US) and its Belgian partner UCB on Tuesday announced that their experimental lupus treatment, dupilumab, met its primary goal in late-stage trials, a surprising reversal after the drug failed in early mid-stage studies. If the success is confirmed in a second late-stage study, it could provide new treatment options for lupus patients, especially in an area where trials have failed and approved therapies are limited. The companies plan to start the second study later this year.